- Report
- January 2026
- 368 Pages
Global
From €5186EUR$5,850USD£4,512GBP
- Report
- January 2026
- 275 Pages
Global
From €5186EUR$5,850USD£4,512GBP
- Report
- January 2026
- 282 Pages
Global
From €5186EUR$5,850USD£4,512GBP
- Report
- January 2026
- 193 Pages
Global
From €5186EUR$5,850USD£4,512GBP
- Report
- January 2026
- 193 Pages
Global
From €5186EUR$5,850USD£4,512GBP
- Report
- January 2026
- 184 Pages
Global
From €5186EUR$5,850USD£4,512GBP
- Report
- January 2026
- 367 Pages
Global
From €5186EUR$5,850USD£4,512GBP
- Report
- November 2025
- 150 Pages
Global
From €3324EUR$3,750USD£2,892GBP
- Report
- November 2025
- 150 Pages
Global
From €3324EUR$3,750USD£2,892GBP
- Report
- November 2025
- 150 Pages
Global
From €3324EUR$3,750USD£2,892GBP
- Report
- September 2025
- 150 Pages
Global
From €3945EUR$4,450USD£3,432GBP
- Report
- November 2025
- 148 Pages
Global
From €3502EUR$3,950USD£3,047GBP
- Report
- January 2025
- 141 Pages
Global
From €3502EUR$3,950USD£3,047GBP
- Report
- June 2025
- 400 Pages
Global
From €4387EUR$4,949USD£3,817GBP
- Report
- July 2025
- 249 Pages
Global
From €4428EUR$4,995USD£3,853GBP
- Report
- October 2025
- 160 Pages
Global
From €3502EUR$3,950USD£3,047GBP
- Report
- March 2025
- 86 Pages
Global
From €3500EUR$4,229USD£3,152GBP
- Report
- November 2025
- 150 Pages
Global
From €3413EUR$3,850USD£2,969GBP
€4299EUR$4,850USD£3,741GBP
- Report
- December 2024
- 368 Pages
Global
From €4388EUR$4,950USD£3,818GBP
- Report
- June 2024
- 252 Pages
Global
From €2172EUR$2,450USD£1,890GBP

The Drug Eluting Balloon (DEB) market is a subset of the medical device industry. DEBs are used to treat peripheral artery disease (PAD) and coronary artery disease (CAD). They are designed to deliver a drug directly to the site of the blockage, allowing for improved efficacy and reduced side effects. DEBs are typically composed of a balloon catheter with a drug-eluting coating. The drug is released when the balloon is inflated, allowing for targeted delivery of the drug to the affected area.
DEBs have been shown to be effective in treating PAD and CAD, and are increasingly being used in clinical practice. They offer a minimally invasive alternative to traditional treatments such as stenting and bypass surgery.
Some companies in the DEB market include Medtronic, Boston Scientific, Abbott, and B. Braun. Show Less Read more